Crossmark

Development of a 1:1-binding biparatopic anti-TNFR2 antagonist by reducing signaling activity through epitope selection

Crossref DOI link: https://doi.org/10.1038/s42003-023-05326-8

Published Online: 2023-09-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Akiba, Hiroki https://orcid.org/0000-0002-1450-5873
Fujita, Junso https://orcid.org/0000-0003-1273-3917
Ise, Tomoko

Nishiyama, Kentaro https://orcid.org/0000-0002-2238-2463
Miyata, Tomoko https://orcid.org/0000-0002-5543-7459
Kato, Takayuki https://orcid.org/0000-0002-8879-6685
Namba, Keiichi https://orcid.org/0000-0003-2911-5875
Ohno, Hiroaki https://orcid.org/0000-0002-3246-4809
Kamada, Haruhiko https://orcid.org/0000-0002-2478-3818
Nagata, Satoshi https://orcid.org/0000-0001-9156-5215
Tsumoto, Kouhei https://orcid.org/0000-0001-7643-5164
Funding

Funding for this research was provided by:

MEXT | Japan Society for the Promotion of Science (JP21K06453)

MEXT | Japan Society for the Promotion of Science (JP20K22630)

Takeda Science Foundation

Kyoto University Foundation

Japan Agency for Medical Research and Development (JP21am0101117)

Japan Agency for Medical Research and Development (JP22ama121003)

Japan Agency for Medical Research and Development (JP17pc0101020)

Japan Agency for Medical Research and Development (JP22ak0101099)

MEXT | Japan Science and Technology Agency (JPMJOP1861)

JEOL YOKOGUSHI Research Alliance Laboratory of Osaka University
License Information

Text and Data Mining valid from 2023-09-27

Version of Record valid from 2023-09-27
More Information

Article History

Received: 7 March 2023

Accepted: 6 September 2023

First Online: 27 September 2023

Competing interests

: H.A., S.N., and K.T. filed a patent related to the described biparatopic antibodies (WO2021200840). H.K. and S.N. are co-founders of Epitope Science Co., Ltd. The other authors have no conflicts of interest to declare.

Document is current

Any future updates will be listed below